Your session is about to expire
← Back to Search
Lenvatinib + Pembrolizumab for Endometrial Cancer
Study Summary
This trial will study whether pembrolizumab and lenvatinib prolongs progression free survival and overall survival for endometrial cancer patients when compared to standard treatment.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2024 Phase 2 trial • 57 Patients • NCT03004183Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My cancer is a specific type affecting the uterus.I have received an organ or tissue transplant from another person.I have had more than one chemotherapy treatment for endometrial cancer, but no more than two that included platinum.I have been treated with drugs targeting blood vessel growth or drugs that boost the immune system.I stopped a specific immune treatment due to severe side effects.My cancer progressed after 1 platinum-based treatment.I have a severe abnormal connection between my organs.I have not had significant coughing up of blood or tumor bleeding in the last 2 weeks.I have had serious heart problems or a stroke in the last year.I still have side effects from recent major surgery.I have or had lung inflammation treated with steroids.I have a tumor that can be measured and has been confirmed by a review.I am fully active or restricted in physically strenuous activity but can do light work.I had radiation therapy over 3 weeks ago, except for bone lesion treatment, which was over 2 weeks ago, and I've recovered from side effects.I haven't had any cancer except for certain skin cancers or treated in-situ cancers in the last 2 years.My scans show cancer has spread to major blood vessels.I had cancer treatment within the last 28 days and have no major side effects.I am currently being treated for an infection.I have an autoimmune disease, other than psoriasis, treated in the last 2 years.I have not received a live vaccine in the last 30 days.My heart's pumping ability is below normal.I have been diagnosed with endometrial carcinoma.My cancer has come back or spread from its original site.I have a tumor biopsy for MMR status testing.My brain metastases are not stable.I have an immune system disorder or have been on high-dose steroids or other immune-weakening medicines recently.I am HIV positive.I have a condition that affects how my body absorbs medication.
- Group 1: Lenvatinib 20 mg + Pembrolizumab 200 mg
- Group 2: Treatment of Physician's Choice
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Pembrolizumab has received FDA approval, correct?
"Pembrolizumab is considered safe by our team at Power, who gave it a score of 3. This is due to this being a Phase 3 trial, which means that there is not just some data supporting efficacy, but multiple rounds of data supporting safety."
Can people with certain medical conditions participate in this research project?
"This trial is no longer recruiting patients. According to the study's clinicaltrials.gov page, it was first posted on 6/11/2018 and was last updated on 9/23/2022. However, there are presently 291 clinical trials actively enrolling participants with endometrial neoplasms and 2147 trials for Pembrolizumab actively recruiting participants."
How many people are being signed up to participate in this test?
"This study is not recruiting patients at this time, as the last update was on September 23rd, 2022. Out of the 291 clinical trials for endometrial neoplasms and 2147 trials for Pembrolizumab, this study is not the only one looking for patients."
What are some of the more common reasons that Pembrolizumab is prescribed?
"Pembrolizumab is often used to melanoma that cannot be surgically removed. It is also useful for treating microsatellite instability high, neuroblastoma (nb), and high risk of recurrence."
Could you please tell me more about other Pembrolizumab research projects?
"Pembrolizumab was first studied in 1997 at Spectrum Health Hospital - Butterworth Campus. So far, there have been 1980 completed trials. Out of the 2147 active trials, many are based in San Antonio, Texas."
What other similar trials have been conducted in the past?
"Pembrolizumab has been the focus of 2147 clinical trials in 82 countries and 4095 cities. The first Pembrolizumab trial began in 1997 and completed Phase 3 in 300 patients. Between 1997 and now, there have been 1980 more trials."
Share this study with friends
Copy Link
Messenger